127 research outputs found
Wide binaries as a critical test of Classical Gravity
Modified gravity scenarios where a change of regime appears at acceleration
scales have been proposed. Since for systems the
acceleration drops below at scales of around 7000 AU, a statistical
survey of wide binaries with relative velocities and separations reaching
AU and beyond should prove useful to the above debate. We apply the
proposed test to the best currently available data. Results show a constant
upper limit to the relative velocities in wide binaries which is independent of
separation for over three orders of magnitude, in analogy with galactic flat
rotation curves in the same acceleration regime. Our results are
suggestive of a breakdown of Kepler's third law beyond
scales, in accordance with generic predictions of modified gravity theories
designed not to require any dark matter at galactic scales and beyond.Comment: accepted for publication in EPJ
Observational biases in Lagrangian reconstructions of cosmic velocity fields
Lagrangian reconstruction of large-scale peculiar velocity fields can be
strongly affected by observational biases. We develop a thorough analysis of
these systematic effects by relying on specially selected mock catalogues. For
the purpose of this paper, we use the MAK reconstruction method, although any
other Lagrangian reconstruction method should be sensitive to the same
problems. We extensively study the uncertainty in the mass-to-light assignment
due to luminosity incompleteness, and the poorly-determined relation between
mass and luminosity. The impact of redshift distortion corrections is analyzed
in the context of MAK and we check the importance of edge and finite-volume
effects on the reconstructed velocities. Using three mock catalogues with
different average densities, we also study the effect of cosmic variance. In
particular, one of them presents the same global features as found in
observational catalogues that extend to 80 Mpc/h scales. We give recipes,
checked using the aforementioned mock catalogues, to handle these particular
observational effects, after having introduced them into the mock catalogues so
as to quantitatively mimic the most densely sampled currently available galaxy
catalogue of the nearby universe. Once biases have been taken care of, the
typical resulting error in reconstructed velocities is typically about a
quarter of the overall velocity dispersion, and without significant bias. We
finally model our reconstruction errors to propose an improved Bayesian
approach to measure Omega_m in an unbiased way by comparing the reconstructed
velocities to the measured ones in distance space, even though they may be
plagued by large errors. We show that, in the context of observational data, a
nearly unbiased estimator of Omega_m may be built using MAK reconstruction.Comment: 29 pages, 21 figures, 6 tables, Accepted by MNRAS on 2007 October 2.
Received 2007 September 30; in original form 2007 July 2
Quaternary structure independent folding of voltage-gated ion channel pore domain subunits
Every voltage-gated ion channel (VGIC) has a pore domain (PD) made from four subunits, each comprising an antiparallel transmembrane helix pair bridged by a loop. The extent to which PD subunit structure requires quaternary interactions is unclear. Here, we present crystal structures of a set of bacterial voltage-gated sodium channel (BacNaV) 'pore only' proteins that reveal a surprising collection of non-canonical quaternary arrangements in which the PD tertiary structure is maintained. This context-independent structural robustness, supported by molecular dynamics simulations, indicates that VGIC-PD tertiary structure is independent of quaternary interactions. This fold occurs throughout the VGIC superfamily and in diverse transmembrane and soluble proteins. Strikingly, characterization of PD subunit-binding Fabs indicates that non-canonical quaternary PD conformations can occur in full-length VGICs. Together, our data demonstrate that the VGIC-PD is an autonomously folded unit. This property has implications for VGIC biogenesis, understanding functional states, de novo channel design, and VGIC structural origins
The Gas Content in Galactic Disks: Correlation with Kinematics
We consider the relationship between the total HI mass in late-type galaxies
and the kinematic properties of their disks. The mass for galaxies with
a wide variety of properties, from dwarf dIrr galaxies with active star
formation to giant low-brightness galaxies, is shown to correlate with the
product ( is the rotational velocity, and is the radial
photometric disks scale length), which characterizes the specific angular
momentum of the disk. This relationship, along with the anticorrelation between
the relative mass of HI in a galaxy and , can be explained in terms of the
previously made assumption that the gas density in the disks of most galaxies
is maintained at a level close to the threshold (marginal) stability of a
gaseous layer to local gravitational perturbations. In this case, the
regulation mechanism of the star formation rate associated with the growth of
local gravitational instability in the gaseous layer must play a crucial role
in the evolution of the gas content in the galactic disk.Comment: revised version to appear in Astronomy Letters, 8 pages, 5 EPS
figure
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence from both laboratory and clinical studies to suggest that in addition to inhibiting platelet aggregation, antithrombotic medications have shear-dependent effects, potentiating thrombus fragility and/or enhancing endogenous fibrinolysis. Such shear-dependent effects, potentiating the fragility of the growing thrombus and/or enhancing endogenous thrombolytic activity, likely contribute to the clinical effectiveness of such medications. It is not clear how much these effects relate to the measured inhibition of platelet aggregation in response to specific agonists. These effects are observable only with techniques that subject the growing thrombus to arterial flow and shear conditions. The effects of antithrombotic medications on thrombus stability and ways of assessing this are reviewed herein, and it is proposed that thrombus stability could become a new target for pharmacological intervention.Peer reviewedFinal Published versio
Determinants of elevated healthcare utilization in patients with COPD
<p>Abstract</p> <p>Background</p> <p>Chronic obstructive pulmonary disease (COPD) imparts a substantial economic burden on western health systems. Our objective was to analyze the determinants of elevated healthcare utilization among patients with COPD in a single-payer health system.</p> <p>Methods</p> <p>Three-hundred eighty-nine adults with COPD were matched 1:3 to controls by age, gender and area of residency. Total healthcare cost 5 years prior recruitment and presence of comorbidities were obtained from a computerized database. Health related quality of life (HRQoL) indices were obtained using validated questionnaires among a subsample of 177 patients.</p> <p>Results</p> <p>Healthcare utilization was 3.4-fold higher among COPD patients compared with controls (p < 0.001). The "most-costly" upper 25% of COPD patients (n = 98) consumed 63% of all costs. Multivariate analysis revealed that independent determinants of being in the "most costly" group were (OR; 95% CI): age-adjusted Charlson Comorbidity Index (1.09; 1.01 - 1.2), history of: myocardial infarct (2.87; 1.5 - 5.5), congestive heart failure (3.52; 1.9 - 6.4), mild liver disease (3.83; 1.3 - 11.2) and diabetes (2.02; 1.1 - 3.6). Bivariate analysis revealed that cost increased as HRQoL declined and severity of airflow obstruction increased but these were not independent determinants in a multivariate analysis.</p> <p>Conclusion</p> <p>Comorbidity burden determines elevated utilization for COPD patients. Decision makers should prioritize scarce health care resources to a better care management of the "most costly" patients.</p
Taking the Measure of the Universe: Precision Astrometry with SIM PlanetQuest
Precision astrometry at microarcsecond accuracy has application to a wide
range of astrophysical problems. This paper is a study of the science questions
that can be addressed using an instrument that delivers parallaxes at about 4
microarcsec on targets as faint as V = 20, differential accuracy of 0.6
microarcsec on bright targets, and with flexible scheduling. The science topics
are drawn primarily from the Team Key Projects, selected in 2000, for the Space
Interferometry Mission PlanetQuest (SIM PlanetQuest). We use the capabilities
of this mission to illustrate the importance of the next level of astrometric
precision in modern astrophysics. SIM PlanetQuest is currently in the detailed
design phase, having completed all of the enabling technologies needed for the
flight instrument in 2005. It will be the first space-based long baseline
Michelson interferometer designed for precision astrometry. SIM will contribute
strongly to many astronomical fields including stellar and galactic
astrophysics, planetary systems around nearby stars, and the study of quasar
and AGN nuclei. SIM will search for planets with masses as small as an Earth
orbiting in the `habitable zone' around the nearest stars using differential
astrometry, and could discover many dozen if Earth-like planets are common. It
will be the most capable instrument for detecting planets around young stars,
thereby providing insights into how planetary systems are born and how they
evolve with time. SIM will observe significant numbers of very high- and
low-mass stars, providing stellar masses to 1%, the accuracy needed to
challenge physical models. Using precision proper motion measurements, SIM will
probe the galactic mass distribution and the formation and evolution of the
Galactic halo. (abridged)Comment: 54 pages, 28 figures, uses emulateapj. Submitted to PAS
Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy
BACKGROUND:Prior research has demonstrated that medication persistence (continued acquisition of therapy over time) is far from optimal among patients with glaucoma. The purpose of the present study was to evaluate persistence with prostaglandin analogs among glaucoma patients in the first therapy year using a modification of a previously published technique.METHODS:This retrospective analysis of medical and pharmacy claims database included treatment-naive patients dispensed bimatoprost, latanoprost, or travoprost between 1/1/04-12/31/04. "Index agent" was defined as the first agent filled; "index date" was defined as the fill date. Follow-up continued for 358 days. Persistence measures for first therapy year were: (1) whether last fill had sufficient days supply to achieve medication possession at year's end, and (2) number of days for which the index agent was available (days covered). Associations between index agent and medication possession (logistic regression) and days covered (linear regression) were evaluated. Models were adjusted for gender, age, and previous ocular hypertension diagnosis.RESULTS:7873 patients met inclusion criteria (bimatoprost, n = 1464; latanoprost, n = 4994; travoprost, n = 1415). Medication possession was 28% and days covered was 131 when using the unadjusted (pharmacy-reported) days supply estimates and rose to 47-48% and days covered to 228-236 days when days supply was imputed. Compared to latanoprost, odds of achieving medication possession at first year's end were 26-34% lower for bimatoprost and 34-36% lower for travoprost (p [less than or equal to] 0.001 for all comparisons). Days covered in the first year were 21-29 days lower for bimatoprost and 33-42 days lower for travoprost (p [less than or equal to] 0.001 for all comparisons). Failure to refill the index agent within the initial 90 days was a strong predictor of poor persistence. CONCLUSIONS:Persistence with ocular prostaglandin therapy remains a problem. Latanoprost users had greater odds of achieving medication possession and had more days covered during the first therapy year.The results of this study were presented in part at the Annual Meeting of
the Association for Research in Vision and Ophthalmology, April 27 to May
1, 2008, in Fort Lauderdale, Florida, USA and at the International Society for
Pharmacoeconomics and Outcomes Research 13th Annual International
Meeting, May 3 to May 7, 2008, in Toronto, Canada.
The research was supported by Pfizer Inc, New York, New York, USA.
Assistance in styling the paper for journal submission was provided by Jane
G. Murphy, PhD, of Zola Associates and was funded by Pfizer Inc, New York,
New York, USA. Sonali Shah, BS Pharm, RPh, MPH provided the impetus and
helpful support and advice for design of this study
African American patients with gout: efficacy and safety of febuxostat vs allopurinol
<p>Abstract</p> <p>Background</p> <p>African Americans are twice as likely as Caucasians to develop gout, but they are less likely to be treated with urate-lowering therapy (ULT). Furthermore, African Americans typically present with more comorbidities associated with gout, such as hypertension, obesity, and renal impairment. We determined the efficacy and safety of ULT with febuxostat or allopurinol in African American subjects with gout and associated comorbidities and in comparison to Caucasian gout subjects.</p> <p>Methods</p> <p>This is a secondary analysis of the 6-month Phase 3 CONFIRMS trial. Eligible gouty subjects with baseline serum urate (sUA) ≥ 8.0 mg/dL were randomized 1:1:1 to receive febuxostat 40 mg, febuxostat 80 mg, or allopurinol (300 mg or 200 mg depending on renal function) daily. All subjects received gout flare prophylaxis. Primary efficacy endpoint was the proportion of subjects in each treatment group with sUA < 6.0 mg/dL at the final visit. Additional endpoints included the proportion of subjects with mild or with moderate renal impairment who achieved a target sUA < 6.0 mg/dL at final visit. Adverse events (AEs) were recorded throughout the study.</p> <p>Results</p> <p>Of the 2,269 subjects enrolled, 10.0% were African American and 82.1% were Caucasian. African American subjects were mostly male (89.5%), obese (BMI ≥ 30 kg/m<sup>2</sup>; 67.1%), with mean baseline sUA of 9.8 mg/dL and mean duration of gout of 10.4 years. The proportions of African American subjects with a baseline history of diabetes, renal impairment, or cardiovascular disease were significantly higher compared to Caucasians (<it>p </it>< 0.001). ULT with febuxostat 80 mg was superior to both febuxostat 40 mg (<it>p </it>< 0.001) and allopurinol (<it>p </it>= 0.004). Febuxostat 40 mg was comparable in efficacy to allopurinol. Significantly more African American subjects with mild or moderate renal impairment achieved sUA < 6.0 mg/dL in the febuxostat 80 group than in either the febuxostat 40 mg or allopurinol group (<it>p </it>< 0.05). Efficacy rates in all treatment groups regardless of renal function were comparable between African American and Caucasian subjects, as were AE rates.</p> <p>Conclusions</p> <p>In African American subjects with significant comorbidities, febuxostat 80 mg is significantly more efficacious than either febuxostat 40 mg or allopurinol 200/300 mg. Febuxostat was well tolerated in this African American population.</p> <p>Please see related article: <url>http://www.biomedcentral.com/1741-7015/10/15</url></p
- …